In conclusion: The percentage of CD34+CD38- SCs burden at diagnosis reflects the CML disease’s behavior and is considered a biomarker for predicting CML patients’ response to first-line Tyrosine kinase inhibitors (TKI) therapy. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.